Objective: The purpose of this study was to investigate the clinical effect of Danhong injection with atorvastatin on endothelial function and inflammation factors in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) surgery

and provide clinical basis for ACS therapy. Method: From 2012/5 to 2014/5

we collected 125 ACS cases treated with PCI in our hospital and divided them into 2 groups randomly

with 62 cases in control group and 63 cases in observation group. Besides conventional treatment

the control group was treated with atorvastatin and the observation group was treated with danhong injection combined with atorvastatin. Before and after treatment

the indexes of endothelial function including endothelin-1 (ET-1)

nitrogen monoxide (NO)

von willebrand factor (vWF) and flow-mediated dilation (FMD)

inflammation factors including tumor necrosis factor-α (TNF-α)

interleukin-1 (IL-1) and C reactive protein (CRP)

as well as complications were observed and compared. Result: Compared with those before treatment

the indexes of endothelial function including ET-1

NO

vWF and FMD were all improved after treatment. However

these indexes decreased more significantly in the observation group than in the control group

and all differences were statistically significant (P<0.05). The inflammation factors including TNF-α

IL-1 and CRP were all decreased after treatment in both groups. However

those decreased more significantly in the observation group than in the control group

with all differences statistically significant (P<0.05). Complications in the observation group was significantly lower than in the control group(7.9% VS 32.3%

P<0.05). Conclusion: Combination treatment of danhong injection and atorvastatin for ACS therapy can improve endothelial function and decrease inflammation factors and is worthy of study and further application in clinical treatment.